Abstract

Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Clin Gastroenterol Hepatol. 2022 Jul;20(7):1609-1612.e1. doi: 10.1016/j.cgh.2021.12.045.Epub 2022 Jan 6.

 

Sarah Frey 1Reezwana Chowdhury 2Caoilfhionn M Connolly 3William A Werbel 4Dorry L Segev 5Alyssa M Parian 6IBD GROUP 2

 

Collaborators

IBD GROUP: 

Evangelos TsipotisSharon Dudley-BrownMark LazarevJoanna M MeliaBrindusa TrutaHuimin YuFlorin M Selaru

 
     

Author information

1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

2Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

3Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

4Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

5Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

6Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: aparian1@Jhmi.edu.

Abstract

Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.